A
Andrew D. Flapan
Researcher at Edinburgh Royal Infirmary
Publications - 74
Citations - 5185
Andrew D. Flapan is an academic researcher from Edinburgh Royal Infirmary. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 26, co-authored 74 publications receiving 4804 citations. Previous affiliations of Andrew D. Flapan include British Heart Foundation & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart)
James Nolan,P D Batin,R. Andrews,Steven Lindsay,P Brooksby,Michael J. Mullen,Wazir Baig,Andrew D. Flapan,Alan J. Cowley,Robin J Prescott,James M.M. Neilson,Keith A.A. Fox +11 more
TL;DR: CHF is associated with autonomic dysfunction, which can be quantified by measuring HRV, and a reduction in SDNN identifies patients at high risk of death and is a better predictor of death due to progressive heart failure than other conventional clinical measurements.
Journal ArticleDOI
18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial
Nikhil Joshi,Alex T. Vesey,Michelle C. Williams,Anoop S V Shah,Patrick A. Calvert,Felicity H. Craighead,Su Ern Yeoh,William Wallace,Donald Salter,Alison Fletcher,Edwin J R van Beek,Andrew D. Flapan,Neal G. Uren,Miles Behan,Nicholas L. Cruden,Nicholas L. Mills,Keith A.A. Fox,James H.F. Rudd,Marc R. Dweck,David E. Newby +19 more
TL;DR: 18)F-NaF PET-CT is the first non-invasive imaging method to identify and localise ruptured and high-risk coronary plaque and is needed to establish whether this method can improve the management and treatment of patients with coronary artery disease.
Journal ArticleDOI
Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment
TL;DR: The current evidence regarding fish oils and cardiovascular disease, their possible mechanism of action, and potential future developments and research strategies are reviewed.
Journal ArticleDOI
Acute Cardiovascular Effects of Apelin in Humans Potential Role in Patients With Chronic Heart Failure
Alan G. Japp,Nicholas L. Cruden,Gareth Barnes,N van Gemeren,J A Mathews,Janet Adamson,Neil R. Johnston,Martin A. Denvir,Ian L. Megson,Andrew D. Flapan,David E. Newby +10 more
TL;DR: Acute apelin administration in humans causes peripheral and coronary vasodilatation and increases cardiac output and represents a novel potential therapeutic target for patients with heart failure.
Journal ArticleDOI
Vascular Effects of Apelin In Vivo in Man
Alan G. Japp,Nicholas L. Cruden,David A.B. Amer,Vivienne K.Y. Li,Ewan B Goudie,Neil R. Johnston,Sushma Sharma,Ilene Neilson,David J. Webb,Ian L. Megson,Andrew D. Flapan,David E. Newby +11 more
TL;DR: Although having no apparent effect on venous tone, apelin causes nitric oxide-dependent arterial vasodilation in vivo in man and merits further clinical investigation to determine its role in cardiovascular homeostasis.